SG/PUT/NOVO-NORDISK B/750/0.1/20.06.25 | Market Closed - Boerse Frankfurt Warrants 12:16:18 04/07/2024 am IST | ||
| 0.61 EUR | +12.96% |
|
| 1 month | -28.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 0.61 | +12.96% |
| 02/24/02 | 0.54 | +8.00% |
| 01/24/01 | 0.5 | -7.41% |
| 28/24/28 | 0.54 | +1.89% |
| 27/24/27 | 0.53 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 12:16 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW981T |
| ISIN | DE000SW981T4 |
| Date issued | 13/05/2024 |
| Strike | 750 kr |
| Maturity | 20/06/2025 (352 Days) |
| Parity | 10 : 1 |
| Emission price | 0.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.9 € |
|---|---|
| Lowest since issue | 0.47 € |
| Spread | 0.02 € |
| Spread % | 3.17% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Warrants
- Warrant
